Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans

Abstract Introduction Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT1A receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE) between tablet and capsule formulations of ulotar...

Full description

Bibliographic Details
Main Authors: Yu-Luan Chen, Hironobu Tsukada, Snezana Milanovic, Lei Shi, Yan Li, Yongcai Mao, Kenneth S. Koblan, Gerald R. Galluppi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-03-01
Series:Neurology and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s40120-023-00459-8